What the GHK-Cu Research Actually Shows, and Where the Evidence Runs Thin

GHK-Cu, the copper complex of a small tripeptide found in human plasma, is often described online as if its benefits were settled. The published record is more uneven. Most of it comes from cell cultures and animal experiments, and the controlled human studies that exist are few, small, topical and decades old.

Much of the interest traces to work such as a 1993 study in the Journal of Clinical Investigation. Researchers implanted wire-mesh wound chambers under the skin of rats and injected them with saline or GHK-Cu; they reported concentration-dependent increases in collagen, glycosaminoglycans, total protein and DNA in the treated chambers, while a control tripeptide had no significant effect.

A 2026 systematic review in Aesthetic Surgery Journal, which searched PubMed, Embase and Cochrane CENTRAL through March 2026, found 20 eligible studies on aesthetic uses. Eighteen were preclinical and two were randomized controlled trials. The authors described consistent preclinical signals on extracellular matrix and inflammation markers, but said the findings were constrained by methodological variability and a limited number of well-designed clinical trials.

The human studies point in different directions. A 1994 multicenter, evaluator-blinded, placebo-controlled trial of a GHK-Cu gel in diabetic neuropathic foot ulcers, published in Wound Repair and Regeneration with several authors affiliated with ProCyte Corporation, reported a median 98.5% closure of plantar ulcers versus 60.8% with vehicle. A 1992 randomized trial in the Journal of Vascular Surgery, with 86 evaluable patients with venous leg ulcers, found no difference between a 0.4% copper tripeptide cream and placebo; silver sulfadiazine outperformed both.

A 2006 randomized study in Archives of Facial Plastic Surgery, in which 13 patients completed follow-up after CO2 laser resurfacing, found no significant objective improvement in redness, wrinkles or overall skin quality with GHK-Cu skin care products, although patient-reported satisfaction was higher. No peer-reviewed randomized trial of injected GHK-Cu in people was identified for this article.

Because the human evidence is thin, GHK-Cu sold as a raw peptide is generally labeled for laboratory research rather than for personal use. QSC Peptidology, an affiliate of this site, sells GHK-Cu labeled for research use at https://www.qscpeptidology.com/products/ghk-cu-50mg-10pack; a research-use label describes how a product is sold, not evidence that it works or is safe in people.

When a claim about GHK-Cu comes up, the useful questions are whether it rests on cells, animals or people, and whether the human study was controlled, how large it was and what route it used. On the current record, mechanistic findings are substantial while human outcome data are sparse and mixed. Anyone weighing a skin or wound product should rely on a licensed clinician and on products with an approved or cleared use, and should treat confident online summaries with caution.